Sepideh Nemat

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

Timothy Brighton, Amit Khot, Simon J. Harrison et al. · Clinical Cancer Research · 2019 · 65 citations

Predictors of response to anti‐<scp>IL</scp>6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase <scp>II</scp> clinical trial data

Deanna E. Morra, Sheila K. Pierson, Dustin Shilling et al. · British Journal of Haematology · 2018 · 49 citations · Full text

Effects of oral pyridoxine upon plasma and 24-hour urinary oxalate levels in normal subjects and stone formers with idiopathic hypercalciuria

Paul Edwards, Sepideh Nemat, Geoffrey Rose · Urological Research · 1990 · 30 citations

Electrolyte Disorder, Urology, Renal Function +8

Plasma oxalate and creatinine and oxalate/creatinine clearance ratios in normal subjects and in primary hyperoxaluria. Evidence for renal hyperoxaluria

G. P. Kasidas, Sepideh Nemat, G Rose · Clinica Chimica Acta · 1990 · 18 citations

Urology, Renal Function, Sodium Homeostasis +12